GlobeNewswire

Talenom reinforces its business in Sweden and expands to Gothenburg and Malmö with the acquisition of Frivision AB, a company focusing on small customer segment

Share

Talenom Plc, Stock exchange release, 1 September 2020 at 11:50 EEST

Talenom reinforces its business in Sweden and expands to Gothenburg and Malmö with the acquisition of Frivision AB, a company focusing on small customer segment

Talenom Plc has made an agreement with the owners of the Swedish accounting company Frivision AB to purchase the entire share capital of the company. The acquired company will support Talenom’s strategic goal of expanding its business into the small customer segment. At the same time, the transaction will strengthen Talenom’s position in the Swedish market in new locations – Gothenburg and Malmö. In the short term, the share transaction will not have any significant impact on Talenom’s financial position or future outlook.

Frivision AB, a provider of accounting services focusing on small customer segment, is an authorised accounting firm with 20 employees based in Stockholm, Gothenburg and Malmö. Frivision Group consists of the parent company, Frivision AB, and seven wholly-owned subsidiaries. The Group’s net sales in the accounting period that ended on 30 April 2020 amounted to SEK 15.1 million (EUR 1.4 million), with year-on-year growth of 16.2%. EBITDA in the accounting period was approximately SEK 60 000 (EUR 6 000) or 0.4% of net sales. 

The transaction price is SEK 15.1 million (EUR 1.4 million), of which SEK 7.55 million (EUR 0.7 million) will be paid in the form of new shares in Talenom Plc, subscribed under a directed share issue for the owners of Frivision. The remainder of the transaction price will be paid in cash and financed with the liquid assets of Talenom Plc. In addition to the transaction price, the seller has the opportunity to receive an additional purchase price of SEK 6.4 million (EUR 0.6 million) at maximum if the financial targets set for the acquired business are reached.

“I am highly satisfied to have Frivision’s team to strengthen our growth in Sweden in new locations and to support the development of our small customer segment, as both of these are strategically important development areas for us. Growth in our operations in Sweden will soon enable us to localise our own technology. We warmly welcome Frivision’s personnel and customers to Talenom. We share a desire to help entrepreneurs to experience the joy of entrepreneurship. We have a common vision of future development in the accounting sector, and this will form a strong foundation on which we can build the future together,” says Otto-Pekka Huhtala, Talenom’s CEO.

“Frivision’s passion has always been to develop the small customer concept for accounting sector, taking into consideration the unique characteristics of the segment. We have already had plenty of success in this, but we need the best technology in the sector and additional resources in order to realise our vision and accelerate growth. Talenom has these resources, and it also shares our outlook for the future of the small customer segment. That is why this acquisition was now such a natural fit,” says Tobias Ryberg, Frivision’s founder and CEO, who will continue as a Talenom employee.

The subscribed 83,362 new shares in the share issue related to the transaction will be registered in the Finnish Trade Register approximately on 3 September 2020. After the registration of the new shares, the number of Talenom Plc shares is 43,146,435 shares in total. The number of shares issued corresponds to 0.19% of all Talenom Plc shares outstanding before the share issue. The new shares will carry shareholders rights as of their registration day. The shares issued in the share issue will be later admitted to trading on the official list of Nasdaq Helsinki Oy.

TALENOM PLC
BOARD OF DIRECTORS

Further information:
Otto-Pekka Huhtala
CEO, Talenom Plc
+358 40 7038 554
otto-pekka.huhtala@talenom.fi

Talenom Plc is an accounting firm established in 1972. Talenom offers a wide range of accounting services as well as other expert and advisory services to support its clients’ business. The company has its own software development and it provides its clients with electronic financing tools.

Talenom Group’s net sales in 2019 amounted to EUR 58.0 million, with an increase of 18.6% compared to 2018. Talenom has a history of strong growth – the average annual increase in net sales was approximately 15.7% between 2005 and 2019.

DISTRIBUTION:
Nasdaq Helsinki
Main media
www.talenom.fi

About GlobeNewswire

GlobeNewswire
GlobeNewswire
One Liberty Plaza - 165 Broadway
NY 10006 New York

https://globenewswire.com

GlobeNewswire is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.

Subscribe to releases from GlobeNewswire

Subscribe to all the latest releases from GlobeNewswire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from GlobeNewswire

Galapagos announces first dosing in MANGROVE Phase 2 trial with GLPG2737 in polycystic kidney disease1.12.2020 22:01:00 CETPress release

Mechelen, Belgium; 1 December 2020, 22.01 CET; Galapagos NV (Euronext & NASDAQ: GLPG) announces first dosing in the new MANGROVE Phase 2 trial with investigational CFTR inhibitor GLPG2737 in patients with autosomal dominant polycystic kidney disease (ADPKD). MANGROVE is a randomized, double-blind, placebo-controlled trial evaluating a once-daily oral dose of GLPG2737. The drug candidate or placebo will be administered for 52 weeks in up to 60 ADPKD patients with rapidly progressing disease. Patients will be randomized in a 2:1 ratio of treatment to placebo. Primary objectives of the trial are to assess the growth of total kidney volume over 52 weeks compared to placebo as well as overall safety and tolerability. Secondary measures include renal function, pharmacokinetics, and pharmacodynamics. Recruitment for the MANGROVE trial is planned in 7 countries in Europe. GLPG2737 is a CFTR1 inhibitor which was shown to be well tolerated by patients in previous clinical trials. It is hypothesi

REC Silicon – Cancellation of subsequent offering1.12.2020 20:13:46 CETPress release

NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN AUSTRALIA, CANADA, JAPAN OR THE UNITED STATES OR ANY OTHER JURISDICTION IN WHICH SUCH RELEASE, PUBLICATION OR DISTRIBUTION WOULD BE UNLAWFUL. Lysaker, 1 December 2020 Reference is made to the stock exchange announcements by REC Silicon ASA (the "Company") on 14 October 2020 and 15 October 2020 regarding the successful completion of a private placement raising gross proceeds of approximately NOK 1,000 million (the "Private Placement") and a potential subsequent offering (the "Subsequent Offering") of up to 18,518,518 new shares directed towards shareholders of the Company as of 14 October 2020 who were not allocated shares in the Private Placement. The Company has decided not to initiate the Subsequent Offering. The background for the cancellation is that the Company's shares have over time traded on the Oslo Stock Exchange, with significant trading volume, at prices below the subscription pric

Bombardier and Alstom Confirm Receipt of All Necessary Regulatory Approvals to Complete Bombardier Transportation Sale to Alstom1.12.2020 18:24:09 CETPress release

MONTRÉAL, Dec. 01, 2020 (GLOBE NEWSWIRE) -- Bombardier (TSX: BBD.B) and Alstom announced today that all necessary regulatory approvals required to complete the sale of Bombardier Transportation to Alstom have been received. Bombardier and Alstom now expect the transaction to close on January 29, 2021. About Bombardier With over 52,000 employees across two business segments, Bombardier is a global leader in the transportation industry, creating innovative and game-changing planes and trains. Our products and services provide world-class transportation experiences that set new standards in passenger comfort, energy efficiency, reliability and safety. Headquartered in Montréal, Canada, Bombardier has production and engineering sites in over 25 countries across the segments of Aviation and Transportation. Bombardier shares are traded on the Toronto Stock Exchange (BBD). In the fiscal year ended December 31, 2019, Bombardier posted revenues of $15.8 billion. News and information are availab

FDA approves Xolair® (omalizumab) for adults with nasal polyps1.12.2020 18:07:00 CETPress release

Xolair is the first biologic for the treatment of nasal polyps that targets and blocks immunoglobulin E (IgE), a key driver of inflammationXolair is now FDA-approved across three diseases and in two formulations, continuing to build on the medicine’s 17 years of patient experience since its initial approval for allergic asthma Basel, 01 December 2020 - Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that the U.S. Food and Drug Administration (FDA) has approved the company’s supplemental Biologics License Application (sBLA) for Xolair® (omalizumab) for the add-on maintenance treatment of nasal polyps in adult patients 18 years of age and older with inadequate response to nasal corticosteroids.1 Nasal polyps can lead to a loss of smell and nasal congestion, and frequently co-occur with other respiratory conditions, such as allergies and asthma. With this approval, Xolair is now the first biologic for the treatment of nasal polyps that targets and blocks immunoglobulin E (IgE), a key d

Tecan raises forecast for the full year of 2020 based on continued extraordinary demand for COVID-19 related products1.12.2020 18:02:00 CETPress release

Sales growth now expected to be in the low to mid-teens percentage range in local currenciesReported EBITDA margin now forecasted above 20.5% of sales Männedorf, Switzerland, 1 December, 2020 – Based on the strong business performance year to date, as well as on the high order backlog and the continued elevated demand for COVID-19 related products, the Tecan Group (SIX Swiss Exchange: TECN) once again raised its outlook for full-year sales and reported EBITDA margin. These updated projections continue to be based on the assumptions that also for the remainder of the year supply chains and freight logistics remain undisrupted and all production sites stay fully operational. Based on continued strong demand for a number of product lines to help in the global fight against the coronavirus pandemic, Tecan now forecasts sales growth for full-year 2020 to be in the low to mid-teens percentage range in local currencies (latest guidance from August 12, 2020: “high single-digit percentage range

Touax: Successful asset refinancing - Containers Business1.12.2020 17:45:00 CETPress release

PRESS RELEASE Paris, December 1, 2020 – 5.45 p.m. YOUR OPERATIONAL LEASING SOLUTION FOR SUSTAINABLE TRANSPORTATION Successful asset refinancing - Containers Business Touax announces today that it has successfully refinanced asset-backed facilities of its Container division for a total of US$ 75 million, versus US$ 60 million previously, combining a Term Loan of US$ 37 million and a Revolving Credit Facility (RCF) of US$ 38 million with a two-year maturity. The documentation provides for an accordion option, allowing the line to be scaled up to US$ 85 million, to support growth. This operation allows the refinancing of the existing portfolio of assets as well as the financing of future investments. Touax Container Asset Finance Ltd will thus continue to invest for its development, particularly in the purchase of equipment for leasing purpose. Financing is granted by ABN AMRO Bank N.V., ING Belgium SA / NV and NIBC Bank N.V. Touax was advised by Stephenson Harwood (Legal Counsel). “We ar